Latest News

Launch of adalimumab biosimilar Amjevita postponed


 

Amgen, maker of the adalimumab biosimilar Amjevita (adalimumab-atto) has reached an agreement with AbbVie, manufacturer of the originator adalimumab Humira, that halts marketing of Amjevita in the United States until 2023 and in Europe until 2018, according to a company statement.

The deal between the two manufacturers settles a patent infringement lawsuit that AbbVie brought against Amgen after it received Food and Drug Administration approval in September 2016 for seven of Humira’s nine indications: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis. Amjevita is not approved for two of Humira’s indications, hidradenitis suppurativa and uveitis.

Amgen said in its statement that AbbVie will grant patent licenses for the use and sale of Amjevita worldwide, on a country-by-country basis, with current expectations that marketing will begin in Europe on Oct. 16, 2018, and in the United States on Jan. 31, 2023. Amjevita is named Amgevita in Europe.

Recommended Reading

VIDEO: Cardiovascular events in rheumatoid arthritis have decreased over decades
MDedge Family Medicine
Studies examine methotrexate starting dose for RA in monotherapy and combinations
MDedge Family Medicine
Oral contraceptive use linked to lower rheumatoid arthritis risk
MDedge Family Medicine
Worsening osteoporosis care for RA patients shows need for action
MDedge Family Medicine
FDA approves second adalimumab biosimilar for multiple conditions
MDedge Family Medicine
VIDEO: Prescription-strength ibuprofen worsens blood pressure more than other NSAIDs
MDedge Family Medicine
Vaccinate and consider tofacitinib monotherapy to prevent herpes zoster in RA
MDedge Family Medicine
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Family Medicine
Ultrasound’s value for arthralgia may be to rule out IA
MDedge Family Medicine
‘Multimorbidities’ in RA make impact on treatment efficacy, disease activity
MDedge Family Medicine

Related Articles

  • News from the FDA/CDC

    FDA approves biosimilar adalimumab

    There are “no clinically meaningful differences” between Amgen’s biosimilar adalimumab (Amjevita) and AbbVie’s branded product Humira, the Food...